Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2
inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been
merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is
provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well
as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-
N8-hydroxyoctanediamide 6